(VIANEWS) – Novo Nordisk A/S (NVO), AvalonBay Communities (AVB), Atlanticus Holdings Corporation (ATLC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Novo Nordisk A/S (NVO)
25.8% sales growth and 88.77% return on equity
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Earnings Per Share
As for profitability, Novo Nordisk A/S has a trailing twelve months EPS of $2.46.
PE Ratio
Novo Nordisk A/S has a trailing twelve months price to earnings ratio of 43.56. Meaning, the purchaser of the share is investing $43.56 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 88.77%.
Moving Average
Novo Nordisk A/S’s worth is higher than its 50-day moving average of $101.56 and way higher than its 200-day moving average of $90.18.
Previous days news about Novo Nordisk A/S(NVO)
- According to Zacks on Monday, 15 January, "Some other top-ranked stocks in the Medical space are Amphastar Pharmaceuticals, Inc. (AMPH Quick QuoteAMPH – Free Report) and Novo Nordisk A/S (NVO Quick QuoteNVO – Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). "
2. AvalonBay Communities (AVB)
13.5% sales growth and 8.07% return on equity
As of September 30, 2023, the Company owned or held a direct or indirect ownership interest in 296 apartment communities containing 89,240 apartment homes in 12 states and the District of Columbia, of which 17 communities were under development and one community was under redevelopment. The Company is an equity REIT in the business of developing, redeveloping, acquiring and managing apartment communities in leading metropolitan areas in New England, the New York/New Jersey Metro area, the Mid-Atlantic, the Pacific Northwest, and Northern and Southern California, as well as in the Company's expansion regions of Raleigh-Durham and Charlotte, North Carolina, Southeast Florida, Dallas and Austin, Texas, and Denver, Colorado.
Earnings Per Share
As for profitability, AvalonBay Communities has a trailing twelve months EPS of $6.57.
PE Ratio
AvalonBay Communities has a trailing twelve months price to earnings ratio of 27.78. Meaning, the purchaser of the share is investing $27.78 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.07%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Dec 27, 2023, the estimated forward annual dividend rate is 6.6 and the estimated forward annual dividend yield is 3.62%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 22.1% and positive 20% for the next.
Sales Growth
AvalonBay Communities’s sales growth is 22.6% for the current quarter and 13.5% for the next.
3. Atlanticus Holdings Corporation (ATLC)
10.9% sales growth and 20.68% return on equity
Atlanticus Holdings Corporation provides credit and related financial services and products to customers the United States. It operates in two segments, Credit as a Service, and Auto Finance. The Credit as a Service segment originates a range of consumer loan products, such as private label and general purpose credit cards originated by lenders through various channels, including retail and healthcare, direct mail solicitation, digital marketing, and partnerships with third parties; and offers credit to their customers for the purchase of various goods and services, including consumer electronics, furniture, elective medical procedures, healthcare, educational services, and home-improvements by partnering with retailers and service providers. In addition, it offers loan servicing, such as risk management and customer service outsourcing for third parties; and engages in testing and investment activities in consumer finance technology platforms. The Auto Finance segment purchases and/or services loans secured by automobiles from or for a pre-qualified network of independent automotive dealers and automotive finance companies in the buy-here, pay-here, and used car business. This segment also provides floor plan financing and installment lending products. Further, the company invests in and services portfolios of credit card receivables. Atlanticus Holdings Corporation was founded in 1996 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, Atlanticus Holdings Corporation has a trailing twelve months EPS of $4.12.
PE Ratio
Atlanticus Holdings Corporation has a trailing twelve months price to earnings ratio of 8.7. Meaning, the purchaser of the share is investing $8.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.68%.
Volume
Today’s last reported volume for Atlanticus Holdings Corporation is 37316 which is 97.53% above its average volume of 18891.
Yearly Top and Bottom Value
Atlanticus Holdings Corporation’s stock is valued at $35.86 at 10:22 EST, way below its 52-week high of $43.70 and way above its 52-week low of $21.65.
Revenue Growth
Year-on-year quarterly revenue growth declined by 4.4%, now sitting on 344.78M for the twelve trailing months.
Sales Growth
Atlanticus Holdings Corporation’s sales growth is 13.7% for the current quarter and 10.9% for the next.
4. AMETEK (AME)
10.8% sales growth and 16.51% return on equity
Ametek names dalip puri cfo, succeeding william burke, with effect from April 2Burke joined AMETEK in 1987 and was named Vice President, Investor & Corporate Relations in 1999, Vice President, Investor Relations and Treasurer in 2007, and Senior Vice President, Comptroller & Treasurer in 2012.
AMETEK, Inc. manufactures and sells electronic instruments and electromechanical devices in North America, Europe, Asia, and South America. It operates in two segments, Electronic Instruments (EIG) and Electromechanical (EMG). The company's EIG segment offers advanced instruments for the process, aerospace, power, and industrial markets; process and analytical instruments for the oil and gas, petrochemical, pharmaceutical, semiconductor, automation, and food and beverage industries; and instruments to the laboratory equipment, ultra-precision manufacturing, medical, and test and measurement markets.Its EMG segment offers engineered electrical connectors and electronics packaging to protect sensitive devices and mission-critical electronics; precision motion control products for data storage, medical devices, business equipment, automation, and other applications; high-purity powdered metals, strips and foils, specialty clad metals, and metal matrix composites; motor-blower systems and heat exchangers for use in thermal management, military, commercial aircraft, and military ground vehicles; and motors for use in commercial appliances, fitness equipment, food and beverage machines, hydraulic pumps, and industrial blowers. This segment also operates a network of aviation maintenance, repair, and overhaul facilities. In addition, the company offers clinical and educational communication solutions. AMETEK, Inc. was incorporated in 1930 and is headquartered in Berwyn, Pennsylvania.
Earnings Per Share
As for profitability, AMETEK has a trailing twelve months EPS of $5.52.
PE Ratio
AMETEK has a trailing twelve months price to earnings ratio of 29.61. Meaning, the purchaser of the share is investing $29.61 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.51%.
Volume
Today’s last reported volume for AMETEK is 800983 which is 16.71% below its average volume of 961704.
5. Great Elm Capital Corp. (GECC)
9.4% sales growth and 14.3% return on equity
Great Elm Capital Corporation is a business development company which specializes in loan and mezzanine, middle market investments. The fund prefers to invest in media, commercial services and supplies, healthcare, telecommunication services, communications equipment. It typically makes equity investments between $3 million and $10 million in companies with revenues between $3 million and $75 million.
Earnings Per Share
As for profitability, Great Elm Capital Corp. has a trailing twelve months EPS of $1.71.
PE Ratio
Great Elm Capital Corp. has a trailing twelve months price to earnings ratio of 6.23. Meaning, the purchaser of the share is investing $6.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.3%.
Sales Growth
Great Elm Capital Corp.’s sales growth is 24.6% for the ongoing quarter and 9.4% for the next.
6. Regeneron Pharmaceuticals (REGN)
8.6% sales growth and 17.22% return on equity
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Earnings Per Share
As for profitability, Regeneron Pharmaceuticals has a trailing twelve months EPS of $35.09.
PE Ratio
Regeneron Pharmaceuticals has a trailing twelve months price to earnings ratio of 26.59. Meaning, the purchaser of the share is investing $26.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.22%.
Yearly Top and Bottom Value
Regeneron Pharmaceuticals’s stock is valued at $933.20 at 10:22 EST, under its 52-week high of $935.37 and way above its 52-week low of $684.81.
Previous days news about Regeneron Pharmaceuticals(REGN)
- According to Zacks on Monday, 15 January, "Some better-ranked stocks in the drug/biotech sector worth considering are Fusion Pharmaceuticals (FUSN Quick QuoteFUSN – Free Report) , Novo Nordisk (NVO Quick QuoteNVO – Free Report) and Regeneron Pharmaceuticals (REGN Quick QuoteREGN – Free Report) , all three sporting a Zacks Rank #1 (Strong Buy). "
- According to Zacks on Monday, 15 January, "Some other top-ranked biotech companies are Regeneron Pharmaceuticals (REGN Quick QuoteREGN – Free Report) , Sarepta Therapeutics (SRPT Quick QuoteSRPT – Free Report) and Acadia (ACAD Quick QuoteACAD – Free Report) ."
7. Restaurant Brands International (QSR)
7.3% sales growth and 30.52% return on equity
Restaurant Brands International Inc. operates as a quick-service restaurant company in Canada, the United States, and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and other food products. It is also involved in owning and franchising BK, a fast-food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, French fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana-style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS quick service restaurants that offer meats and cheese, chopped salads, chili and soups, signature and other sides, soft drinks, and local specialties. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.
Earnings Per Share
As for profitability, Restaurant Brands International has a trailing twelve months EPS of $2.9.
PE Ratio
Restaurant Brands International has a trailing twelve months price to earnings ratio of 27.05. Meaning, the purchaser of the share is investing $27.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.52%.
Moving Average
Restaurant Brands International’s worth is above its 50-day moving average of $73.07 and higher than its 200-day moving average of $71.39.
Sales Growth
Restaurant Brands International’s sales growth is 7.2% for the present quarter and 7.3% for the next.
